USPTO serial 79455621
CYTOSPIRE
Reviewed by CopyMark Law Group
Status 640Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- DANTZLER, LAUREN ALEXANDRIA
- Law office
- TMO LAW OFFICE 129
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with CYTOSPIRE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Anna King
Anna King Banner & Witcoff, Ltd.71 South Wacker Drive, Suite 3600Chicago, IL 60606United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the prevention and treatment of cancer and tumours; pharmaceutical preparations for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; biological preparations for medical purposes; biological preparations for the prevention and treatment of cancer and tumours; biological preparations for use in the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; biological preparations for use in the prevention and treatment of cancer and tumours; biopharmaceuticals for the treatment of cancer; antibodies; diagnostic reagents for medical use. | ACTIVE | — |
| 042 | Scientific and technological services; scientific research; pharmaceutical research and development services; medical research services; drug development services; laboratory analysis; laboratory research; laboratory testing; testing of pharmaceuticals; pharmaceutical research and development services in the field of oncology and immunotherapy; pharmaceutical research and development of pharmaceuticals and drugs for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; medical research services in the field of oncology and immunotherapy; medical research services for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; drug development services in the field of oncology and immunotherapy; drug development services for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; laboratory research and testing of pharmaceuticals in the field of oncology and immunotherapy; laboratory research and testing of pharmaceuticals for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; research and development services in the field of antibodies; research and development in the field of biotechnology; development of antibodies; development of antibodies for use in the field of oncology and immunotherapy; information, consultancy and advice in relation to the aforesaid services. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 3, 2026 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Nov 3, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 3, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 3, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 3, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 27, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 26, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 29, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 13, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 13, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 6, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |